Skip to main content

Advertisement

Table 5 US FDA-approved human mAbs

From: Development of therapeutic antibodies for the treatment of diseases

No.AntibodyBrandnameCompanyApproval#TargetReferencesTechnology
1AdalimumabHumiraAbbott_Laboratories2002TNFαden Broeder et al. [178]Phage display
2PanitumumabVectibixAmgen2006EGFRTyagi et al. [179]XenoMouse
3UstekinumabStelaraJohnson & Johnson2009IL-12Bartlett et al. [17]HuMabMouse
4CanakinumabIlarisNovartis2009IL-1βChurch et al. [18]HuMabMouse
5GolimumabSimponiJohnson & Johnson/Merck2009TNFαZhou et al. [19]HuMabMouse
6OfatumumabArzerraGlaxoSmithKline (Genmab)2009CD20Coiffier et al. [20]HuMabMouse
7DenosumabProlia, XgevaAmgen2010RANKLReddy et al. [21]XenoMouse
8BelimumabBenlystaGlaxoSmithKline2011BCAFDing et al. [180]Phage display
9IpilimumabYervoyBristol-Myers Squibb2011CTLA-4Morse et al. [22]HuMabMouse
10RamucirumabCyramzaEli Lilly (ImClone)2014VEGFR2Krupitskaya et al. [181]Phage display
11NivolumabOpdivoBristol-Myers Squibb2014PD-1Wolchok et al. [23]HuMabMouse
12AlirocumabPraluentSanofi and Regeneron2015PCSK9Roth et al. [24]Veloclmmune Mouse
13DaratumumabDarzalexJohnson & Johnson (Genmab)2015CD38de Weers et al. [25]HuMabMouse
14NecitumumabPortrazzaEli Lilly (ImClone)2015EGFRKuenen et al. [182]Phage display
15EvolocumabRepathaAmgen2015PCSK9Hirayama et al. [26]XenoMouse
16SecukinumabCosentyxNovartis2015IL-17αChioato et al. [27]XenoMouse
17OlaratumabLartruvoEli Lilly2016PDGFRαChiorean et al. [28]HuMabMouse
18AtezolizumabTecentriqRoche2016PD-L1McDermott et al. [183]Phage display
19AvelumabBavencioPfizer2017PD-L1Boyerinas et al. [184]Phage display
20BrodalumabSiliqValeant Pharmaceuticals2017IL-17RPapp et al. [29]XenoMouse
21DupilumabDupixentSanofi and Regeneron2017IL-4RWenzel et al. [30]Veloclmmune Mouse
22DurvalumabImfinziMedimmune/AstraZeneca2017PD-L1Antonia et al. [31]XenoMouse
23GuselkumabTremfyaJassen Biotech2017IL-23Sofen et al. [185]Phage display
24SarilumabKevzaraSanofi and Regeneron2017IL-6RHuizinga et al. [32]Veloclmmune Mouse
25ErenumabAimovigNovartis and Amgen2018CGRPRTepper et al. [33]XenoMouse
26CemiplimabLibtayoRegeneron2018PD-1Migden et al. [34]Veloclmmune Mouse
27EmapalumabGamifantNovImmmune2018IFNγAl-Salama ZT [186]Phage display
28Moxetumomab pasudodoxLumoxitiMedImmune/AstraZeneca2018CD22Kreitman et al. [187]Phage display
  1. #Year of the first US FDA approval